UK Scientists Race to Develop Vaccine Against Deadly Bundibugyo Ebola Strain
A team of British researchers is making significant strides toward a vaccine targeting one of the most lethal — and least understood — strains of Ebola virus. Scientists at the UK Health Security Agency (UKHSA), working in collaboration with academic partners, are developing a vaccine candidate targeting the Bundibugyo species of Ebola, with clinical trials potentially beginning within months. The news has reignited global conversation around pandemic preparedness and the persistent gaps in our infectious disease arsenal.
What Is Actually Happening
The Bundibugyo strain of Ebola — first identified in Uganda's Bundibugyo district in 2007 — carries a case fatality rate of approximately 30 to 40 percent. Unlike the more widely known Zaire strain, which caused the devastating 2014–2016 West African outbreak and for which approved vaccines now exist, Bundibugyo has remained largely neglected by vaccine developers. That is now changing.
UK researchers have developed a vaccine candidate using a chimpanzee adenovirus vector — a delivery mechanism similar to the technology underpinning the Oxford-AstraZeneca COVID-19 vaccine. Early preclinical data has shown promising immune responses, and the team is reportedly on track to submit for Phase 1 trial approval in the coming months. If authorised, initial human trials would assess safety and immunogenicity in healthy adult volunteers.
Why This Is Trending Right Now
The timing of this announcement is no coincidence. The Democratic Republic of Congo (DRC) has experienced repeated Ebola outbreaks over the past decade, and global health authorities remain on edge. More recently, a 2022 outbreak in Uganda — caused specifically by the Bundibugyo-related Sudan strain — exposed just how unprepared the world remains for non-Zaire Ebola variants. That outbreak killed 55 people and left health workers scrambling without a validated vaccine to deploy.
There is also growing political momentum. The 100 Days Mission, a global initiative backed by the G7 and spearheaded by organisations like CEPI (Coalition for Epidemic Preparedness Innovations), has pushed for vaccine candidates to reach trials within 100 days of a pathogen being identified as a threat. The UK's progress on Bundibugyo fits neatly within this framework — and demonstrates that sustained investment in neglected pathogens can yield real results.
Key Details Worth Knowing
The Bundibugyo Threat
Bundibugyo Ebola virus is transmitted through direct contact with the blood, bodily fluids, or organs of infected persons or animals. Fruit bats are considered the natural reservoir host. Outbreaks have historically been confined to Central and East Africa, but increased human encroachment into forested areas raises spillover risk. There have been two confirmed outbreaks to date — in Uganda in 2007 and the DRC in 2012 — but experts warn that surveillance gaps mean unreported cases likely exist.
The Vaccine Technology
The adenovirus vector platform has already proven itself in multiple disease areas, offering faster manufacturing timelines and a well-understood safety profile. The Bundibugyo vaccine candidate encodes viral glycoprotein antigens, designed to prompt the immune system to recognise and neutralise the virus before serious infection takes hold.
The Broader Impact
If successful, this vaccine would be a genuine milestone — filling a critical gap that has existed since Bundibugyo was first classified. Beyond protecting populations in outbreak-prone regions, it would also provide a template for how quickly vaccine development can move when institutional commitment and funding are aligned. Healthcare workers operating in affected areas — consistently the highest-risk group during outbreaks — stand to benefit most immediately from an approved preventive tool.
The development also signals a maturing of post-COVID lessons. Governments and research institutions are increasingly recognising that waiting for an outbreak before investing in vaccines is a dangerous and costly strategy. Proactive development, even for pathogens currently considered low-risk, is now being treated as a matter of national and global security.
What to Expect Next
Assuming regulatory clearance proceeds smoothly, Phase 1 trials could begin before the end of 2025, with initial safety results available within a year of trial initiation. Broader efficacy trials — which require larger populations and ideally some degree of outbreak conditions — would follow if early data holds up. Partnerships with African health authorities and international bodies like the WHO will be critical to ensuring the vaccine reaches the populations who need it most, rather than sitting on shelves in high-income countries. The world has learned hard lessons about vaccine equity; this is an opportunity to apply them early.